Geniko Nosokomeio Thessalonikis “Papageorgiou” brings its patients and physicians quicker access to innovative medical treatments by joining Clinerion’s Patient Network Explorer platform.
Based in the city of Thessaloniki, Greece, “Papageorgiou” General Hospital has 746 beds and specializes in research on multiple sclerosis, dementia, pemphigus, plaque psoriasis, chronic kidney disease (anemia, diabetes mellitus type 2, bone metabolism in dialysis), ischemic heart disease and acute coronary syndromes, ventricular arrhythmias/dysfunction, prevention of sudden cardiac death, atrial fibrillation, heart failure, in various cancer areas (incl. breast cancer, non-small-cell lung cancer, urothelial/bladder cancer, gastric cancer, renal cell cancer, ovarian cancer, prostate cancer), bladder disorders (incl. neurogenic bladder disorder, overactive bladder disorder,) urinary tract infections, erectile dysfunction, pathogenesis, vascular function and complications of cardiovascular risk factors and diseases such as essential hypertension, diabetes mellitus, hyperlipidemia, stroke etc. The hospital runs approximately 62 new clinical trials per year.
With the hospital joining Patient Network Explorer, patients at Geniko Nosokomeio Thessalonikis “Papageorgiou” will be matched to clinical trials being run by international pharmaceutical companies on innovative medical interventions, as well as those being run by the hospital’s own academic researchers. This gives patients and physicians at the hospital access to treatment options and supports the acceleration of the introduction of these treatments into the market.
“With our experience, expertise and infrastructure, our hospital is in a strong position to support international trials,” says Vasileios Papas, Chairman of the Board of the hospital. “We are proud to have been recognized for infrastructure quality for implementation of clinical trials, fast-track administrative procedures, and a friendly organizational environment by the SFEE (the Hellenic Association of Pharmaceutical Companies).”
“Clinerion is thrilled to further expand our coverage of the Greek patient population through the Papageorgiou General Hospital,” says Ian Rentsch, CEO of Clinerion. “We already cover patients in Athens, and this will greatly benefit patients in the area of Thessaloniki, Greece’s second largest cosmopolitan area, in getting earlier access to medical innovations.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.